Correlation between Treatment Outcomes and Serum Vitamin D Levels As Well As Infliximab Trough Concentration among Chinese Patients with Crohn’s Disease

Table 4

The influence of vitamin D level at enrollment on clinical outcomes at the week 14 and week 38 IFX treatment in Crohn’s disease patients.

Time point	Outcomes	Vit-D level at enrollment			Chi-square
		Deficiency	Insufficiency	Sufficiency
Week 14	Biochemical remission	39/49 (79.60)	7/9 (77.80)	2/2 (100)	0.409	1
	Clinical remission	38/54 (70.40)	11/16 (68.80)	4/6 (66.70)	0.239	1
Week 38	Biochemical remission	34/44 (77.30)	1/2 (50)	0/1 (0)	3.725	0.156
	Clinical remission	34/40 (85)	7/7 (100)	5/5 (100)	0.932	0.774
	Endoscopic remission	29/39 (74.40)	11/14 (78.60)	5/5 (100)	1.197	0.689
	Endoscopic response	27/39 (69.20)	8/14 (57.10)	4/5 (80)	1.06	0.666

Abbreviations: Vit-D: vitamin D; CD: Crohn’s disease; IFX: infliximab.